{
    "nctId": "NCT00444587",
    "briefTitle": "A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.",
    "officialTitle": "A Multicenter Phase II Trial of Trastuzumab (Herceptin) Continuation in Combination With 2nd-line Chemotherapies After Progression on a 1st-line Chemotherapy Combined With Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer (Treatment Beyond Progression, TBP)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 114,
    "primaryOutcomeMeasure": "Median Time to Disease Progression",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* female patients, \\>= 18 years of age;\n* metastatic breast cancer;\n* HER2 overexpression (IHC 3+ and/or FISH positive);\n* disease progression during or after previous 1st line chemotherapy + Herceptin;\n* scheduled to receive 2nd line chemotherapy.\n\nExclusion Criteria:\n\n* concurrent immunotherapy or hormonal therapy;\n* anthracyclines as part of previous 1st line chemotherapy or planned 2nd line chemotherapy;\n* cardiac toxicity during previous 1st line chemotherapy + Herceptin;\n* history of other malignancy within last 5 years.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}